Lexicon Pharmaceuticals, Inc. is downgraded to Hold due to repeated FDA rejections of ZYNQUISTA for T1D and catalysts. Read more on LXRX stock here.
Lexicon Pharma (LXRX) prices 32M-share offering at $1.30 and $41M+ private placement to fund R&D and working capital—get the key details now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results